louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03039660: Feasibility and Efficacy Study of Student Wellness Online Course for Medical Students
Official title: Evidence-Based Online Curriculum to Improve Sleep in Medical Students: A Multisite Trial to Assess Efficacy and Feasibility of RefreshMD
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Student Wellness
Lead sponsor: Stanford University
Sponsor class: OTHER
First posted: 2017-02-01
Enrollment: 250
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study aims to investigate the feasibility and efficacy of online student wellness courses for improving medical student mental health and well-being.


Eligibility criteria: Inclusion Criteria:

* Full-time medical student at a participating medical school
* Will remain enrolled as full-time medical student throughout duration of study

Exclusion Criteria:

* Not a full-time medical student at a participating medical school

Primary outcomes:
measure: Enrollment numbers per course
timeFrame: 2 weeks
measure: Views per video
timeFrame: Throughout the course (6 weeks)
measure: Number of actively engaged students per course
timeFrame: Throughout the course (6 weeks)
Secondary outcomes:
measure: Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Related Impairment
timeFrame: Through study completion (4 months)
measure: PROMIS Sleep Disturbance
timeFrame: Through study completion (4 months)
measure: PROMIS Depression
timeFrame: Through study completion (4 months)
measure: Stanford Medical Student Burnout Questionnaire
timeFrame: Through study completion (4 months)
Other outcomes:
Locations:
city: Stanford
country: United States
facility: Stanford University
state: California
city: Saint Louis
country: United States
facility: Washington University in St Louis
state: Missouri
city: Piscataway
country: United States
facility: Rutgers Robert Wood Johnson
state: New Jersey
Study officials:
affiliation: Stanford University graduate, Penn Medicine Fellow
name: Sara G Cadman, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05808660: Questionable Health Behaviors and Their Distal and Proximal Correlates
Official title: Questionable Health Behaviors and Their Distal and Proximal Correlates: Protocol for a Nationally Representative Survey in Serbia
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Questionable Health Behaviors and Their Distal and Proximal Correlates
Keywords: TCAM/ iNAR/ distal predictors /proximal predictors / irrational mindset
Lead sponsor: University of Belgrade
Sponsor class: OTHER
First posted: 2023-04-11
Enrollment: 1043
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: general population

Brief summary: The goals of the study:

1. to investigate the frequency of Traditional, Complementary and Alternative Medicine use (TCAM) and intentional Non-adherence to medical recommendations (iNAR) in the general population in Serbia, as well as their mutual relations.
2. to examine the distribution of irrational beliefs in the general population;
3. to explore the relationships between TCAM and iNAR behaviors on the one hand and variables of personality, thinking styles and cognitive reflection on the other, with a major assumption that these relationships will be mediated by the domain of irrational beliefs and socio-political attitudes.

Participants will respond to a battery of instruments assessing TCAM use and iNAR, as well as, sociodemographics and health-related variables (such as health status, chronic diseases, BMI, etc.), distal psychological (i.e. personality, thinking disposition and styles) and proximal psychological, variables, (i.e. the irrational mindset, as well as socio-political beliefs and attitudes).

Data will be collected on the probabilistic household sample representative for the general population in Serbia (N=1043).


Eligibility criteria: Inclusion Criteria:

* must be at least 18 years of age

Exclusion Criteria:

* the inability to understand the Serbian language
* failure to pass any of the four attention-check questions

Primary outcomes:
measure: Traditional, complementary and alternative medicine (TCAM) use
timeFrame: baseline
measure: intentional non-adherence to official medical recommendations (iNAR)
timeFrame: baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Belgrade
country: Serbia
facility: Faculty of Philosophy
Study officials:
affiliation: Department of Psychology, Faculty of Philosophy, University of Belgrade
name: Goran Knezevic, prof.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06904560: The Relation Between BSS Solution Temperature and Endothelial Cells and Post Phaco Discomfort
Official title: The Relation Between BSS Solution Temperature and Endothelial Cells and Post Phaco Discomfort
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Corneal Diseases
Keywords: cornea, cataract
Lead sponsor: Sohag University
Sponsor class: OTHER
First posted: 2025-04-01
Enrollment: 40
Sex: ALL
Minimum age (years): 40
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: patients underwent phacoemulsification , balanced saline solution used during the operation will be at room temperature in one group and cool 2.7 c in the other group. the patients will be followed for 3 months after phacoemulsification regarding corneal endothelial cells and anterior segment inflammatory signs

Detailed description: patients underwent phacoemulsification , balanced saline solution used during the operation will be at room temperature in one group and cool 2.7 c in the other group. the patients will be followed for 3 months after phacoemulsification regarding corneal endothelial cells and anterior segment inflammatory signs

Eligibility criteria: Inclusion Criteria:

* patients with cataract
* more than 40 years
* no glaucoma
* no retinal abnormalities
* no retinal abnormalities

Exclusion Criteria:

patients with corneal diseases patients less than 40 patients with previous eye surgery

Primary outcomes:
measure: endothelial cell count
timeFrame: 3 months
Secondary outcomes:
measure: incidence of anterior segment inflammation
timeFrame: 3 months
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04313660: Anlotinib In Combination With PD-1/L1 Inhibitor As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study
Official title: Anlotinib In Combination With PD-1/L1 Inhibitor As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: NSCLC
Anlotinib
PD-1/L1 Inhibitor
Lead sponsor: Wuhan Union Hospital, China
Sponsor class: OTHER
First posted: 2020-03-18
Enrollment: 33
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Anlotinib In Combination With PD-1/L1 Inhibitor As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study


Eligibility criteria: Inclusion Criteria:

1. The subjects volunteered to join the study and signed the informed consent form. They had good compliance and cooperated with the follow-up;
2. Patients between 18-75 years old;
3. Extensive small cell lung cancer confirmed by histopathology (according to Veterans Administration lung study group, Valg stage) and did not progress after 4-6 cycles (21 days as a cycle) of first-line standard chemotherapy platinum combined with etoposide \[complete remission (CR), partial remission (PR) or stable (SD) according to recist1.1 standard\];
4. The time interval between the first TRT and the end of the last chemotherapy should be less than or equal to 6 weeks;
5. The life expectancy shall be at least 3 months;
6. ECoG score: 0-1

Exclusion Criteria:

1. Small cell lung cancer patients with other pathological types of tumor species;
2. Patients with pathological fracture in bone metastasis of small cell lung cancer;
3. Patients with central nervous system metastasis;
4. Patients who have received chest radiotherapy before;
5. Patients who have used vasotargeted drugs (such as bevacizumab, sunitinib, etc.) including enrotinib and immunosuppressive agents before;
6. Imaging (CT or MRI) showed that the distance between the tumor focus and the large blood vessel was less than or equal to 5 mm, or there was a central tumor invading the local large blood vessel, or there was an obvious cavitary or necrotic tumor in the lung;

Primary outcomes:
measure: progress free survival(PFS)
timeFrame: 1 year
Secondary outcomes:
measure: Overall survival(OS)
timeFrame: 1 year
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03902860: Measurement of the Skin Sympathetic Nerve Activity During Stellate, Thoracic, and Lumbar Sympathetic Ganglia Block
Official title: Recording Sympathetic Nerve Activity From the Skin During Stellate, Thoracic, and Lumbar Sympathetic Ganglia Block : a Pilot Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Chronic Pain Requiring Stellate, Thoracic, and Lumbar Sympathetic Ganglia Blockade
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2019-04-04
Enrollment: 32
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients undergoing stellate, thoracic, or lumbar sympathetic block for control of chronic neuropathic pain

Brief summary: Sympathetic nerve activity can be measured transcutaneously in awake patients by computer-based filtering of raw signal obtained via skin leads attached on the chest and the right arm. Electrocardiogram can be removed by applying a high-pass filter setting of 150 Hz. Electromyogram can be filtered by applying a high-pass filter setting of 500 Hz or a band-pass filter setting of 500-1000 Hz.

Currently, the therapeutic effect of stellate, thoracic, and lumbar sympathetic ganglia block (SGB, TSGB, and LSGB, respectively) in patients with chronic pain is generally evaluated by using thermogram/thermography (change in temperature of the upper or lower extremeties) or questionnaire-based scoring.

However, it is not known whether the skin sympathetic nerve activity (SKNA) can be measured in patients undergoing SGB/TSGB/LSGB and used as an alternative tool for assessing the therapeutic effect of SGB/TSGB/LSGB.

Therefore, we planned this pilot study to observe whether the SKNA can be obtained in patients undergoing SGB/TSGB/LSGB and whether it is well correlated to thermogram or questionnaire-based scoring. If the SKNA is observed and decreases after SGB/TSGB/LSGB, it will be presented in milivolt (uV) and compared to that of pre-block values.


Eligibility criteria: Inclusion Criteria:

* Outpatient patients undergoing stellate, thoracic, and lumbar sympathetic block for chronic pain disease

Exclusion Criteria:

* patients denial
* peripheral vascular disease in the head and the upper extremities.
* prior thoracic sympathectomy/sympathicotomy
* prior resection or ablation (chemically or mechanically) of stellate, thoracic, and lumbar sympathetic
* coagulapathy
* infectious disease
* allergy to local anesthetics

Primary outcomes:
measure: The skin sympathetic nerve activity presented as uV obtained via skin leads.
timeFrame: From the beginning of stellate, thoracic, or lumbar sympathetic block procedure and the next outpatient visiting 4 weeks (an average) after the procedure.
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Department of Anesthesiology and Pain Medicine, Seoul National University Hospital
Study officials:
References:
Clinical trial NCT02973776: Vasoconstriction Trial With LEO 90100 Aerosol Foam
Official title: Vasoconstriction Trial Comparing LEO 90100 With Dermovate Cream, Diprosone Ointment, Elocon Cream, Locoid Ointment and LEO 90100 Vehicle
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Psoriasis Vulgaris
Lead sponsor: LEO Pharma
Sponsor class: INDUSTRY
First posted: 2016-11-25
Enrollment: 36
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Vasoconstriction study with LEO 90100

Detailed description: This study compares the pharmacodynamic activity of LEO 90100 with Dermovate cream, Diprosone ointment, Elocon cream, Locoid ointment and LEO 90100 vehicle using a human skin blanching test

Eligibility criteria: Inclusion Criteria:

* Subjects demonstrating adequate vasoconstriction to Diprosone® ointment within 15 days prior to dosing (unoccluded application of Diprosone® ointment for 4-6 hours must show a visual score of skin blanching of at least one unit (visual scale (0-4)).
* Subjects without signs of skin irritation/disease/disorders/symptoms or blemishes on test sites (e.g. erythema, dryness, roughness, scaling, scars, moles, sunburn).

Exclusion Criteria:

* Abnormal pigmentation of the skin or skin type that could, in any way, confound interpretation of the trial results (skin type V and VI on the Fitzpatrick scale).
* Female subjects who are breastfeeding.

Primary outcomes:
measure: Mean of two visual skin blanching scores for each treatment measured 2 hours after 16 hours application under non-occlusive conditions
timeFrame: 18 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Nice
country: France
facility: CPCAD
state: Cedex
Study officials:
References:
Clinical trial NCT04342676: Lymph Node Ratio and Kras Mutation in R Colon Cancer
Official title: Lymph Node Ratio and Kras Mutation in Risk Stratification of Colon Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Colon Cancer Stage III
Lead sponsor: Mansoura University
Sponsor class: OTHER
First posted: 2020-04-13
Enrollment: 433
Sex: ALL
Minimum age (years): 16
Maximum age (years): 70
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: clinical impact of LN ratio with Kras expression in colon cancer

Detailed description: LNR and K ras were evaluated with correlated with different clinicopathological parameters of the patients, PFS and OS.

Eligibility criteria: Inclusion Criteria:

* Stage III colon cancer

Exclusion Criteria:

* Stage I, II, IV

Primary outcomes:
measure: LNR and K ras were evaluated with correlated with different clinicopathological parameters (Gender, CEA, tumor size, tumor grade and response to treatment).
timeFrame: 2 years
Secondary outcomes:
measure: LNR and K ras were evaluated and ASSOCIATION with PFS and OS.
timeFrame: 2 years
Other outcomes:
Locations:
city: Mansoura
country: Egypt
facility: Mansoura University Oncology Center
state: Ad Daqahliyah
Study officials:
affiliation: Oncology Center Mansoura University
name: Tawfik A Elkhodary, MD
role: STUDY_CHAIR
References:
Clinical trial NCT05736276: Empathy Levels Among Undergraduate Medical Students in Karachi, Pakistan - a Cross-sectional Study
Official title: Empathy Levels Among Undergraduate Medical Students in Karachi, Pakistan - a Cross-sectional Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Empathy
Keywords: empathy
medical students
Pakistan
surveys and questionnaires
observational study
Lead sponsor: Ziauddin University
Sponsor class: OTHER
First posted: 2023-02-21
Enrollment: 463
Sex: ALL
Minimum age (years): 17
Maximum age (years): 24
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Undergraduate medical students enrolled in different years of the academic program were involved to cater to those in the pre-clinical years as well as those receiving clinical exposure.

Brief summary: Empathy is a concept native to the field of medicine. However, over the course of medical school, empathy levels are expected to decline. The aim of this study was to assess the empathy levels amongst medical students in relation to their year of study and specialties of choice in the future. A cross-sectional study was conducted to assess empathy levels among students from medical colleges in Karachi, Pakistan, using an online survey. The total duration of the study was two months. The authors analyzed the data using SPSS version 20. A total of 463 undergraduate medical students participated in this survey.


Eligibility criteria: Inclusion Criteria:

* undergraduate medical students

Exclusion Criteria:

* all the remaining population

Primary outcomes:
measure: Empathy score on the Jefferson Scale of Empathy (JSE)
timeFrame: June 2022 - July 2022
Secondary outcomes:
Other outcomes:
Locations:
city: Karachi
country: Pakistan
facility: Ziauddin University
state: Sindh
Study officials:
References:
Clinical trial NCT04516876: Efficacy Research of Bimanual Intensive Training in Children With Hemiplegic Cerebral Palsy
Official title: Efficacy Research of Bimanual Intensive Training in Children With Hemiplegic Cerebral Palsy
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Cerebral Palsy
Keywords: cerebral palsy, bimanual intensive training, occupational therapy
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2020-08-18
Enrollment: 30
Sex: ALL
Minimum age (years): 5
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This research project aims to investigate the feasibility, efficacy, and acceptability of camp-based model of BIT.


Eligibility criteria: Inclusion Criteria:

1. Diagnosis of cerebral palsy(CP) with one or more affected sides.
2. Considerable nonuse of the affected upper limb (amount-of-use score of the Pediatric Motor Activity Log \< 2.5).
3. No excessive muscle tone (Modified Ashworth Scale ≤ 2 at any joints of the upper limb) before beginning treatment.
4. No severe cognitive, visual, or auditory disorders according to medical documents, parental reports, and the examiner 's clinical observation.
5. No injections of botulinum toxin type A or operations on the upper limb within 6 months.

Primary outcomes:
measure: Score changes of Melbourne Assessment 2
timeFrame: baseline, after one week, after 2 months, after 6 months
Secondary outcomes:
measure: Score changes of Bruininks-Oseretsky Test of Motor Proficiency
timeFrame: baseline, after one week, after 2 months, after 6 months
measure: Score changes of Box and Block test
timeFrame: baseline, after one week, after 2 months, after 6 months
measure: Performance changes of motion analysis
timeFrame: baseline, after one week, after 2 months, after 6 months
measure: Score changes of Pediatric Motor Activity Log-Revised
timeFrame: baseline, after one week, after 2 months, after 6 months
measure: Score changes of ABILHAND-kids Questionnaire
timeFrame: baseline, after one week, after 2 months, after 6 months
measure: Score changes of Pediatric Evaluation of Disability Inventory
timeFrame: baseline, after one week, after 2 months, after 6 months
measure: Score changes of Dimensions of Mastery Questionnaire
timeFrame: baseline, after one week, after 2 months, after 6 months
measure: Score changes of Test of Playfulness
timeFrame: from the first day to the sixth day of the intervention
measure: Score changes of Pediatric Engagement Questionnaire
timeFrame: from the first day to the sixth day of the intervention
measure: Score changes of Client Satisfaction Questionnaire
timeFrame: from the first day to the sixth day of the intervention
measure: Score changes of Parenting Stress Index-Short Form
timeFrame: baseline, after one week, after 2 months, after 6 months
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: National Taiwan University, Department of Occupational Therapy
Study officials:
References:
Clinical trial NCT01840176: Prophylactic Modified McCall Culdoplasty During Total Laparoscopic Hysterectomy
Official title: Prophylactic Modified McCall Culdoplasty During Total Laparoscopic Hysterectomy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Vaginal Vault Prolapse
Sexual Function
Keywords: McCall culdoplasty
Total laparoscopic hysterectomy
Vaginal vault prolapse
Sexual function
Lead sponsor: University of North Carolina, Chapel Hill
Sponsor class: OTHER
First posted: 2013-04-25
Enrollment: 50
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: The purpose of this study is to assess the feasibility of performing prophylactic McCall culdoplasty at the time of total laparoscopic hysterectomy. The investigators will also be measuring pelvic support (using POP-Q) and sexual function before and at different time points (up to 12 months) postoperatively.

The investigators hypothesize that women undergoing the McCall culdoplasty will not have different immediate surgical outcomes (operative time, etc) and may have better pelvic support and sexual function in the future.


Eligibility criteria: Inclusion Criteria:

* Women aged 18-99 undergoing elective laparoscopic hysterectomy for benign indications with surgeons in the division of Advanced Laparoscopy and Pelvic Pain at UNC-Chapel Hill.

Exclusion Criteria:

* Current symptomatic or asymptomatic pelvic organ prolapse as measured by the Pelvic Organ Prolapse Quantification (POPQ) system.
* Pregnancy
* Non-English speaking
* Unable to provide informed consent
* Pathology causing an obliterated cul-de-sac

Primary outcomes:
measure: Feasibility
timeFrame: 6 months
Secondary outcomes:
measure: Pelvic support
timeFrame: 12 months
measure: Sexual function
timeFrame: 12 months
Other outcomes:
Locations:
city: Chapel Hill
country: United States
facility: University of North Carolina at Chapel Hill
state: North Carolina
Study officials:
affiliation: UNC Chapel Hill Dept of OB/GYN
name: Kumari Hobbs, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: UNC Chapel Hill Dept of OB/GYN
name: Matthew Siedhoff, MD
role: STUDY_DIRECTOR
References:
citation: Till SR, Hobbs KA, Moulder JK, Steege JF, Siedhoff MT. McCall Culdoplasty during Total Laparoscopic Hysterectomy: A Pilot Randomized Controlled Trial. J Minim Invasive Gynecol. 2018 May-Jun;25(4):670-678. doi: 10.1016/j.jmig.2017.10.036. Epub 2017 Nov 8.